Michael Weller

Michael Weller

Department of Neurology, University Hospital of Zurich

Affiliated withUniversity Hospital of Zurich

Research Area

Biography

Michael Weller has not added Biography.
If you are Michael Weller and would like to personalize this page please email our Author Liaison for assistance.

JoVE Journal Publications

ArticleTotal : 1
Year
An Enzyme- and Serum-free Neural Stem Cell Culture Model for EMT Investigation Suited for Drug Discovery
Publication title

Cited by 8

2016

Other Publications

Article
Year
Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial.

The Lancet. Oncology| PubMed ID: 22578793

2012
2011
2012
2012
Geriatric neuro-oncology: from mythology to biology.

Current opinion in neurology| PubMed ID: 21968549

2011
2011
Clinical trials in neuro-oncology: one step forward, two steps back?

Current opinion in neurology| PubMed ID: 21986679

2011
Costimulatory protein 4IgB7H3 drives the malignant phenotype of glioblastoma by mediating immune escape and invasiveness.

Clinical cancer research : an official journal of the American Association for Cancer Research| PubMed ID: 22080438

2012
Predictive impact of MGMT promoter methylation in glioblastoma of the elderly.

International journal of cancer| PubMed ID: 22139906

2012
2012
Immunology of brain tumors.

Handbook of clinical neurology| PubMed ID: 22230434

2012
2012
Individualized targeted therapy for glioblastoma: fact or fiction?

Cancer journal (Sudbury, Mass.)| PubMed ID: 22290256

2012
2012
2012
2012
Autoimmune myasthenia gravis after sternal fracture.

Case reports in neurology| PubMed ID: 22393321

2012
Is there a world beyond bevacizumab in targeting angiogenesis in glioblastoma?

Expert opinion on investigational drugs| PubMed ID: 22413865

2012
Clinical implications of molecular neuropathology and biomarkers for malignant glioma.

Current neurology and neuroscience reports| PubMed ID: 22427102

2012
2012
2012
2012
More on the immune privilege of glioblastoma.

Neuro-oncology| PubMed ID: 22539528

2012
2012
2012
Pathogenesis and management of primary CNS lymphoma.

Expert review of anticancer therapy| PubMed ID: 22594897

2012
2012
2012
Optimal management of elderly patients with glioblastoma.

Cancer treatment reviews| PubMed ID: 22722053

2013
2012
2012
2012
2012
2012
Microglia: a novel treatment target in gliomas.

Neuro-oncology| PubMed ID: 22851682

2012
2012
2012
Epilepsy meets cancer: when, why, and what to do about it?

The Lancet. Oncology| PubMed ID: 22935237

2012
2012
Epidermal growth factor receptor: a re-emerging target in glioblastoma.

Current opinion in neurology| PubMed ID: 23007009

2012
2012
2012
Prime time for molecular marker diagnostics in neuro-oncology.

Current opinion in neurology| PubMed ID: 23041956

2012
Angiogenesis inhibition: quo vadis?

Neuro-oncology| PubMed ID: 23095501

2012
2012
2013
2013
2013
2013
2013
2013
2013
High-dose praziquantel therapy for cerebral sparganosis.

Journal of neurology| PubMed ID: 23546305

2013
2013
αv-Integrin isoform expression in primary human tumors and brain metastases.

International journal of cancer| PubMed ID: 23661241

2013
2013
2013
2013
2012
2013
2013
2013
2013
2013
2013
Molecular neuro-oncology in clinical practice: a new horizon.

The Lancet. Oncology| PubMed ID: 23896276

2013
2013
Anaplastic oligodendroglioma: a new treatment paradigm and current controversies.

Current treatment options in oncology| PubMed ID: 23907441

2013
Long-term survival in primary glioblastoma with versus without isocitrate dehydrogenase mutations.

Clinical cancer research : an official journal of the American Association for Cancer Research| PubMed ID: 23918605

2013
2013
2013
2014
2013
2013
2013
Tumor-associated edema in brain cancer patients: pathogenesis and management.

Expert review of anticancer therapy| PubMed ID: 24152171

2013
Malignant astrocytoma in elderly patients: where do we stand?

Current opinion in neurology| PubMed ID: 24152817

2013
2013
2013
2014
2013
2014
2014
2014
Treatment of primary CNS lymphoma.

Current treatment options in neurology| PubMed ID: 24343307

2014
2014
mTOR target NDRG1 confers MGMT-dependent resistance to alkylating chemotherapy.

Proceedings of the National Academy of Sciences of the United States of America| PubMed ID: 24367102

2014
2014
2014
2014
2014
2014
2014
2014
2014
2014
2014
ERGO: a pilot study of ketogenic diet in recurrent glioblastoma.

International journal of oncology| PubMed ID: 24728273

2014
2014
2014
2014
2014
Addition of lomustine for bevacizumab-refractory recurrent glioblastoma.

Acta oncologica (Stockholm, Sweden)| PubMed ID: 24862539

2014
MGMT testing--the challenges for biomarker-based glioma treatment.

Nature reviews. Neurology| PubMed ID: 24912512

2014
3-Nitropropionic acid-induced ischemia tolerance in the rat brain is mediated by reduced metabolic activity and cerebral blood flow.

Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism| PubMed ID: 24938399

2014
2014
2014
2014
2014
2012
2014
Primary central nervous system lymphoma in the elderly.

Oncology research and treatment| PubMed ID: 25138296

2014
αvβ3, αvβ5 and αvβ6 integrins in brain metastases of lung cancer.

Clinical & experimental metastasis| PubMed ID: 25150423

2014
2014
2014
2015
2015
Reciprocal modulation of Aβ42 aggregation by copper and homocysteine.

Frontiers in aging neuroscience| PubMed ID: 25249976

2014
2014
How stemlike are sphere cultures from long-term cancer cell lines? Lessons from mouse glioma models.

Journal of neuropathology and experimental neurology| PubMed ID: 25289892

2014
2015
2014
2015
Antiangiogenic therapy for glioblastoma: current status and future prospects.

Clinical cancer research : an official journal of the American Association for Cancer Research| PubMed ID: 25398844

2014
2015
2015
Does cilengitide deserve another chance?-Authors' reply.

The Lancet. Oncology| PubMed ID: 25456377

2014
Differentially regulated miRNAs as prognostic biomarkers in the blood of primary CNS lymphoma patients.

European journal of cancer (Oxford, England : 1990)| PubMed ID: 25534293

2015
2015
2015
MGMT Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial.

Clinical cancer research : an official journal of the American Association for Cancer Research| PubMed ID: 25655102

2015
2015
2015
2015
2015
2015
2015
2015
[Neuro-oncology].

Der Nervenarzt| PubMed ID: 25986916

2015
Malignant optic glioma - the spectrum of disease in a case series.

Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv für klinische und experimentelle Ophthalmologie| PubMed ID: 26004076

2015
2016
The management of lomustine overdose in malignant glioma patients.

Neuro-oncology practice| PubMed ID: 26034630

2014
Corticosteroid use in neuro-oncology: an update.

Neuro-oncology practice| PubMed ID: 26034636

2015
2015
2015
Brain metastasis research: a late awakening.

Chinese clinical oncology| PubMed ID: 26112803

2015
Management of neoplastic meningitis.

Chinese clinical oncology| PubMed ID: 26112812

2015
2015
2015
2016
Management of diffusely infiltrating glioma in the elderly.

Current opinion in oncology| PubMed ID: 26397765

2015
Immunotherapy for glioblastoma: concepts and challenges.

Current opinion in neurology| PubMed ID: 26402401

2015
2015
2016
2015
2016
2014
2015
Neurology--the next 10 years.

Nature reviews. Neurology| PubMed ID: 26503922

2015
Introduction.

Neuro-oncology| PubMed ID: 26516220

2015
Dedication: Andrew T. Parsa.

Neuro-oncology| PubMed ID: 26516222

2015
Immunosuppressive mechanisms in glioblastoma.

Neuro-oncology| PubMed ID: 26516226

2015
2015
2016
New insights into acquired temozolomide resistance in glioblastoma?

Brain : a journal of neurology| PubMed ID: 26598490

2015
2016
2016
2016
Prolonged-release fampridine in multiple sclerosis: Improved ambulation effected by changes in walking pattern.

Multiple sclerosis (Houndmills, Basingstoke, England)| PubMed ID: 26762672

2016
Does Valproic Acid or Levetiracetam Improve Survival in Glioblastoma? A Pooled Analysis of Prospective Clinical Trials in Newly Diagnosed Glioblastoma.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology| PubMed ID: 26786929

2016
2016
Therapeutic options in recurrent glioblastoma--An update.

Critical reviews in oncology/hematology| PubMed ID: 26830009

2016
2016
2016
2016
Glioblastoma.

Handbook of clinical neurology| PubMed ID: 26948367

2016
2016
2016
Therapy for Secondary CNS Involvement in Malignant Lymphomas: No Standard Yet!

Journal of clinical oncology : official journal of the American Society of Clinical Oncology| PubMed ID: 27001566

2016
2016
Quality Issues of Research Antibodies.

Analytical chemistry insights| PubMed ID: 27013861

2016
Corticosteroids compromise survival in glioblastoma.

Brain : a journal of neurology| PubMed ID: 27020328

2016
2016
2016
2016
2016
2016
2016
Glioma.

Nature reviews. Disease primers| PubMed ID: 27188790

2015
2016
Current State of Immune-Based Therapies for Glioblastoma.

American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting| PubMed ID: 27249715

2016
Immunotherapy of Brain Cancer.

Oncology research and treatment| PubMed ID: 27260656

2016
2016
2016
2016
Reply to F. Felix et al and M.F. Fay et al.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology| PubMed ID: 27298403

2016
2016
2016
2016
The Role of Molecular Diagnostics in the Management of Patients with Gliomas.

Current treatment options in oncology| PubMed ID: 27501915

2016